Human Papilloma Virus

Pipeline Programs

Companies

Clinical Trials

1 recruiting

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule

375%

Vaccine

125%

+ 20 programs with unclassified modality

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

MSDIreland - Ballydine

7 programs

quadrivalent human papillomavirusPhase 3

Gardasil9Phase 1

LenvatinibPhase 1Small Molecule

Octavalent HPV with 15 mcg IMX / AAHSPhase 1

Acceptance of Human Papillomavirus Vaccination in Postpartum WomenN/A

+2 more programs

Sharp TherapeuticsPA - Pittsburgh

7 programs

quadrivalent human papillomavirusPhase 3

Gardasil9Phase 1

LenvatinibPhase 1Small Molecule

Octavalent HPV with 15 mcg IMX / AAHSPhase 1

Acceptance of Human Papillomavirus Vaccination in Postpartum WomenN/A

+2 more programs

Angeles TherapeuticsCA - Los Angeles

2 programs

Mobile ClinicPhase 11 trial

Health Messaging via SMSN/A1 trial

Active Trials

NCT03759236Completed3Est. Feb 2020

NCT03953911Unknown3Est. Jun 2020

Merck & Co.RAHWAY, NJ

3 programs

Acceptance of Human Papillomavirus Vaccination in Postpartum WomenN/A1 trial

smearsN/A1 trial

quadrivalent human papillomavirusPHASE_31 trial

Active Trials

NCT00730704Completed150Est. Oct 2012

NCT06255938Unknown200Est. Feb 2026

NCT02382900Unknown500Est. Dec 2015

Alliance PharmaceuticalsUK - Wiltshire

1 program

AFIX OnlyN/A1 trial

Active Trials

NCT03824093Completed225Est. May 2020

Allergy TherapeuticsUK - West Sussex

1 program

Comprehensive Vaccine Promotion PackageN/AVaccine1 trial

Active Trials

NCT03186430Completed168Est. Jul 2018

Oregon TherapeuticsFrance - Paris

1 program

Practice facilitationN/A1 trial

Active Trials

NCT03604393Unknown22,000Est. Jun 2023

Atila BiosystemsCA - Sunnyvale

1 program

Prevention of Cervical Cancer Using the Genotyping Screening and Same-day Self-samplingN/A1 trial

Active Trials

NCT07232355Recruiting5,000Est. Jun 2026

EisaiChina - Liaoning

1 program

LenvatinibPHASE_1Small Molecule

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

Merck & Co.quadrivalent human papillomavirus

Angeles TherapeuticsMobile Clinic

Merck & Co.smears

Atila BiosystemsPrevention of Cervical Cancer Using the Genotyping Screening and Same-day Self-sampling

Oregon TherapeuticsPractice facilitation

Alliance PharmaceuticalsAFIX Only

Angeles TherapeuticsHealth Messaging via SMS

Allergy TherapeuticsComprehensive Vaccine Promotion Package

Merck & Co.Acceptance of Human Papillomavirus Vaccination in Postpartum Women

Clinical Trials (9)

Total enrollment: 28,249 patients across 9 trials

NCT02382900 Merck & Co.quadrivalent human papillomavirus

Two-dose Schedule of Quadrivalent HPV Recombinant Vaccine in 11-year-old Boys in Mexico City

Start: Feb 2015Est. completion: Dec 2015500 patients

Phase 3Unknown

NCT03953911 Angeles TherapeuticsMobile Clinic

Increasing HPV Vaccination Rates Via Educational Interventions in Schools Located Within Cedars-Sinai Catchment Areas

Start: May 2019Est. completion: Jun 20203 patients

Phase 1Unknown

NCT06255938 Merck & Co.smears

Prevalence of HPV (Human Papilloma Virus) and HPV Vaccination Among Victims of Sexual Violence

Start: Feb 2024Est. completion: Feb 2026200 patients

N/AUnknown

NCT07232355 Atila BiosystemsPrevention of Cervical Cancer Using the Genotyping Screening and Same-day Self-sampling

Prevention of Cervical Cancer Using the Genotyping Screening and Same-day Self-sampling

Start: Aug 2023Est. completion: Jun 20265,000 patients

N/ARecruiting

NCT03604393 Oregon TherapeuticsPractice facilitation

Increasing HPV Immunization Rates: The Rural Adolescent Vaccine Enterprise

Start: Jun 2019Est. completion: Jun 202322,000 patients

N/AUnknown

NCT03824093 Alliance PharmaceuticalsAFIX Only

High and Low Resource Interventions to Promote HPV Vaccines

Start: Jul 2018Est. completion: May 2020225 patients

N/ACompleted

NCT03759236 Angeles TherapeuticsHealth Messaging via SMS

Increasing Human Papillomavirus (HPV) Vaccine Uptake Via General Health Messaging

Start: Apr 2018Est. completion: Feb 20203 patients

N/ACompleted

NCT03186430 Allergy TherapeuticsComprehensive Vaccine Promotion Package

PreTeenVax Evaluation

Start: Jun 2017Est. completion: Jul 2018168 patients

N/ACompleted

NCT00730704 Merck & Co.Acceptance of Human Papillomavirus Vaccination in Postpartum Women

Acceptance of Human Papillomavirus Vaccination in Postpartum Women

Start: May 2009Est. completion: Oct 2012150 patients

N/ACompleted

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals

1 actively recruiting trials targeting 28,249 patients

10 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.